The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $193,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on August 20, 2024. The award will fund a 5-year research project titled "The Relationship Between HIV Exposure, Contact Networks, and TB in Children Under 5 Years Old." As part of this project, BMC will collaborate with Stellenbosch University in South Africa, which...
This federal Project Grant award, valued at $1,350,312.00 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products and services to be delivered under this grant include: Developing and optimizing a family of novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect...
This $1,635,882 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop host-directed, pro-apoptotic drug therapies for the treatment of drug-susceptible and multi-drug resistant pulmonary tuberculosis (TB). The primary goals are to: 1) utilize novel pro-apoptotic host-directed therapies to shorten TB treatment regimens from the current 4-6 months...
This $582,959 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to integrate a "Universal Test-and-Connect" (UTC) strategy for HIV prevention and treatment services into two high-volume emergency department (ED) settings in Cape Town, South Africa. The 3-year project, running from September 2024 to September 2027, has three key objectives: Integrate HIV assessment into...
This $106,160 federal Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) aims to investigate the role of DNA methylation in Mycobacterium tuberculosis (MTB) persistence and antibiotic tolerance. The project, led by Stellenbosch University in South Africa, will demonstrate how DNA methylation impacts the MTB stress response, phenotypic drug resistance, and the formation of persister...
This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,252 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct a study entitled "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPROVE TB-HIV)". This 1-year project aims to leverage VUMC's Tuberculosis Sentinel Research Network to perform pharmacokinetic-pharmacodynamic (PK-PD) analyses on first-line...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of Columbia University in the City of New York, totaling $166,541. The grant, titled "RIFAPENTINE IN HIGH DOSES IN PREGNANCY WITH TB (RADIANT-MOMS) STUDY", will be used to conduct research on optimizing tuberculosis (TB) treatment for pregnant and breastfeeding people. The key objectives of the project are to:...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
The Desmond Tutu Health Foundation received a $790,803 Project Grant from the National Institute of Allergy and Infectious Diseases within the Department of Health and Human Services. The grant supports the foundation's work to develop a method for gathering real-time data on factors influencing tuberculosis treatment adherence among men in South Africa.
Specifically, the foundation will integrate modified ecological momentary assessments with medication event monitoring systems and assess the feasibility and usability of the combined platform. An observational cohort study involving 60 participants will then determine preliminary psychosocial and contextual factors influential in TB treatment across the treatment continuum. Results will inform the design of a larger study to identify resources needed at particular times to support adherence and develop a gender-specific intervention. The work directly supports the goals of the National Institutes of Health's Allergy and Infectious Diseases Research program to advance biomedical research on infectious diseases.